Beyond similarities: overall survival and prognostic insights from [¹⁷⁷Lu]Lu-DOTATOC therapy in neuroendocrine tumors
The analysis of OS from routine clinical practice shows that PRRT with [<sup>177</sup>Lu]Lu-DOTATOC is an effective treatment option for NET patients, while generating minimal [<sup>177m</sup>Lu]. The evaluated prognostic factors could help to identify patients who particularly benefit from shorter follow-up intervals.
Authors
- Markus Galler (ORCID: https://orcid.org/0000-0002-5168-9288)
- Tristan Ruhwedel (ORCID: https://orcid.org/0000-0002-4693-5704)
- Christoph Wetz (ORCID: https://orcid.org/0000-0002-7392-1375)
- Julian M.M. Rogasch (ORCID: https://orcid.org/0000-0002-0817-6532)
- Holger Amthauer (ORCID: https://orcid.org/0000-0003-4414-0657)
- P Steinhagen (ORCID: https://orcid.org/0000-0001-8410-4285)
- Imke Schatka (ORCID: https://orcid.org/0000-0002-2628-6145)
Institutions
- Humboldt-Universität zu Berlin (DE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1007/s00259-025-07221-2
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Charité – Universitätsmedizin Berlin